Disease · MONDO_0006486
Comparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 15 of 15
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tebentafusp vs Investigator's Choice: Safety: Number of Participants With Treatment Emergent Adverse Events | 245 of 245 | 105 of 111 | 356 | NCT03070392 | Trial comparisons |
| Tebentafusp vs Investigator's Choice: deaths from any cause | 84 of 245 | 57 of 111 | 356 | NCT03070392 | Trial comparisons |
| Tebentafusp vs Investigator's Choice: serious adverse events | 69 of 245 | 26 of 111 | 356 | NCT03070392 | Trial comparisons |
| Placebo + Dacarbazine 1000 mg/m2 vs Selumetinib 75 mg BD + Dacarbazine 1000 mg/m2: serious adverse events | 2 of 32 | 20 of 97 | 129 | NCT01974752 | Trial comparisons |
| Cohort 1 vs Cohort 2: Disease Control Rate | 18 of 35 | 8 of 19 | 54 | NCT00506142 | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | 15 of 35 | 9 of 19 | 54 | NCT00506142 | Trial comparisons |
| Immunoembolization vs Plain Embolization: serious adverse events | 3 of 26 | 5 of 27 | 53 | NCT00661622 | Trial comparisons |
Arm A (Trametinib) vs Arm B (Trametinib, Akt Inhibitor GSK2141795): Number of Participants With Toxicity, Graded According to the National Cancer Institute CTCAE v4.0, Who Were Treated and Did Not Withdraw Consent | 21 of 21 | 21 of 21 | 42 | NCT01979523 | Trial comparisons |
| Cohort A vs Cohort B: deaths from any cause | 23 of 23 | 14 of 14 | 37 | NCT03207347 | Trial comparisons |
| Cohort A vs Cohort B: serious adverse events | 8 of 23 | 7 of 14 | 37 | NCT03207347 | Trial comparisons |
| Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1) vs Vaccine + Dasatinib (Cycle 1, D1): deaths from any cause | 8 of 9 | 5 of 6 | 15 | NCT01876212 | Trial comparisons |
| Vaccine (Cycle 1, Day 1) + Dasatinib (Cycle 2, D1) vs Vaccine + Dasatinib (Cycle 1, D1): serious adverse events | 7 of 9 | 4 of 6 | 15 | NCT01876212 | Trial comparisons |
| A. Stereotactic Body Radiation Therapy, Ziv-aflibercept vs B. Stereotactic Body Radiation Therapy, Ziv-aflibercept: Incidence of Adverse Events | 0 of 1 | 0 of 2 | 3 | NCT03712904 | Trial comparisons |
| A. Stereotactic Body Radiation Therapy, Ziv-aflibercept vs B. Stereotactic Body Radiation Therapy, Ziv-aflibercept: deaths from any cause | 0 of 1 | 1 of 2 | 3 | NCT03712904 | Trial comparisons |
| A. Stereotactic Body Radiation Therapy, Ziv-aflibercept vs B. Stereotactic Body Radiation Therapy, Ziv-aflibercept: serious adverse events | 0 of 1 | 1 of 2 | 3 | NCT03712904 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006486/comparisons